The collaboration with Samsung will leverage GreenLight's existing manufacturing process, and technology transfer to Samsung will begin immediately, according to both firms.

GreenLight Biosciences is a biotechnology company that was founded in 2008; it is dedicated to making RNA products affordable and accessible. In August 2021, GreenLight announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp.

Samsung Biologics is a contract manufacturing organization that provides integrated end-to-end contract development and manufacturing services.

Samsung Biologics readies mRNA vaccine drug substance production
Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.

TFF, GreenLight partner on powder form mRNA vaccine formulation
To address the cold storage challenge of messenger RNA (mRNA) vaccines, GreenLight Biosciences and TFF Pharmaceuticals have entered into a feasibility...

COVID-19 vaccines may be causing orofacial reactions
The two COVID-19 vaccines being given to patients in the U.S. and other countries have been linked to orofacial adverse drug reactions such as temporary...

Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.